Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says

MT Newswires Live10-14

Neurocrine Biosciences' (NBIX) sales of its Vykat extended-release tablets for hyperphagia are likely to remain "flattish" in the near term, but could return to "some growth" over time, RBC Capital Markets said in a Tuesday note.

While the reported adverse effects have stabilized the past quarters, potentially declining a bit in Q3, a sharp growth in usage is unlikely in the near term, RBC noted.

Neurocrine Biosciences could spur Vykat's sales and improve compliance with optimized patient selection and management, possibly through better prescribing practices, according to RBC. Renewing commercial efforts should also help drive engagement and return to growth, the investment firm added.

RBC estimates Vykat's Q3 sales at $95 million and said it could exceed $600 million in 2030.

RBC has an outperform rating on Neurocrine Biosciences, with a $187 price target.

Price: 137.22, Change: -4.16, Percent Change: -2.94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment